M&A Deal Summary |
|
|---|---|
| Date | 2023-08-23 |
| Target | Apexigen |
| Sector | Life Science |
| Buyer(s) | Pyxis Oncology |
| Deal Type | Add-on Acquisition |
| Advisor(s) | Ladenburg Thalmann & Co. (Financial) Wilson Sonsini Goodrich & Rosati (Legal) |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2018 |
| Sector | Life Science |
| Employees | 44 |
| Revenue | 16M USD (2024) |
Pyxis Oncology specializes in developing a differentiated portfolio of biologics, including antibody-drug conjugates (ADCs) and immunotherapies, to improve the lives of patients with difficult-to-treat cancers. Pyxis Oncology was founded in 2018 and is based in Boston, Massachusetts.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Add-on Acquisition M&A Deals | 1 of 1 |
| State: California M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2023 M&A | 1 of 1 |